Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

CONCLUSION: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an EGFR exon 20 S768T and exon 18 G719C mutation and an epithelial carcinoma with an EGFR D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies.PMID:38591867 | PMC:PMC10896470 | DOI:10.1200/PO.23.00454

Source: Ann Oncol - April 9, 2024 Category: Cancer & Oncology Authors: Monica F Chen Zihe Song Helena A Yu Lecia V Sequist Christine M Lovly Edith P Mitchell Jeffrey A Moscow Robert J Gray Victoria Wang Lisa M McShane Larry V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Yoshie Umemura James V Tricoli Barbar Source Type: research